Composite versus individual biomarkers for predicting clinical benefit to PD-1 blockade in NSCLC 127 3 PPV NPV AUC AUC 95% CI lower limit AUC 95% CI upper limit 31 94 79 64 94 29 94 80 65 95 30 94 82 66 97 24 88 64 43 85 23 80 55 33 76 22 67 43 21 64 22 50 65 44 86 23 100 59 42 76 23 NA 58 40 75 22 NA 64 45 84 23 NA 59 43 76
RkJQdWJsaXNoZXIy MTk4NDMw